Dr. Xue Hou is a chief physician in the Department of Medical Oncology, Sun Yat-sen University Cancer Center (SYSUCC). Dr. Hou obtained her Bachelor's degree in medicine, Master's and Doctor's degree in oncology at Sun Yat-sen University in 2004, 2007, and 2017 respectively. She was a visiting scholar at Memorial Sloan-Kettering Cancer Center (MSKCC) in the New York, U.S.A (the top 1 cancer center in the U.S.A) from 2014 to 2015. Dr. Hou was honored as Excellent Young Talent of SYSUCC in 2014. She has extensive experience and expertise in the field of Medical Oncology, especially in thoracic cancer, including lung cancer, thymic carcinoma and malignant pleural mesothelioma. Dr. Hou was the major member in the multidisciplinary team of brain metastasis in SYSUCC. She has published more than 40 SCI-indexed papers in Journal of Thoracic Oncology, Chest, and Int J Cancer as the first or corresponding author.

Individualized treatment and development of novel drugs for thoracic cancer (including lung cancer, thymic carcinoma and malignant pleural mesothelioma), peri-operation treatment of NSCLC, and brain metastasis of lung cancer.

1999.9—2004.6: Bachelor Degree of Clinical Medicine, Sun Yat-sen University of Medical Sciences (now known as the Medical College of Sun Yat-Sen University)
2004.9—2007.6: Master Degree of Oncology, Sun Yat-sen University Cancer Center;
2013.8—2017.6: Ph.D. of Oncology, Sun Yat-sen University Cancer Center;
2014.8—2015.11: Visiting Scholar of Memorial Sloan-Kettering Cancer Center (New York, USA). 1.Hou X#, Zhou C#, Wu G, Lin W, Xie Z, Zhang H, Yi J, Peng Z, Yin L, Ma C, Chen L*. Efficacy, Safety, and Health-Related Quality of Life with Camrelizumab Plus Pemetrexed and Carboplatin as First-Line treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer with Brain Metastases (CAP-BRAIN): A Multicentre, Open-Label, Single-Arm, Phase 2 Study. J Thorac Oncol. 2023 Feb 2:S1556-0864(23)00092-8.（IF:20.121）
2.Hou X#, Li M#, Wu G#, Feng W#, Su J, Jiang H, Jiang G, Chen J, Zhang B, You Z, Liu Q, Chen L*. Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non-Small Cell Lung Cancer in Patients With Brain Metastases: The GAP BRAIN Open-Label, Randomized, Multicenter, Phase 3 Study. JAMA Netw Open. 2023 Feb 1;6(2):e2255050.. （IF:13.353）
3.Liu Z, Liu M, Hou X*. Near complete response to ceritinib in a pediatric patient with metastatic ALK-rearranged lung adenocarcinoma. Lung Cancer. 2023 Feb; 176: 140-143. PMID: 36640634. （IF:6.081）
4.Li M#, Chen J#, Zhang B#, Yu J, Wang N, Li D, Shao Y, Zhu D, Liang C, Ma Y, Ou Q, Hou X*, Chen L*. Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028). BMC Med. 2022 Nov 14;20(1):398. （IF:11.81）
5.Hou X#, Yang MZ#, Li JB, Tan ZH, Long H, Fu JH, Zhang LJ, Lin P, Yang HX*. Who are the real high-risk patients with pathological T2N0M0 non-small-cell lung cancer that can benefit from adjuvant chemotherapy? ESMO Open. 2022 Jun 7;7(3):100508. （IF:6.88）
6.Li M#, Hou X#, Sai K, Wu L, Chen J, Zhang B, Wang N, Wu L, Zheng H, Zhang J, Mou Y, Chen L*. Immune suppressive microenvironment in brain metastatic non-small cell lung cancer: comprehensive immune microenvironment profiling of brain metastases versus paired primary lung tumors (GASTO 1060). Oncoimmunology. 2022 Mar 31;11(1):2059874.（IF:7.72）
7.Hou X#, Lin S#, Liu Y#, Wang K#, Yu Z, Jia J, Yu J, Zheng W, Bai J, Chang L, Chen J, Li M, Chen L*. Analysis of the tumor microenvironment and mutation burden identifies prognostic features in thymic epithelial tumors. Am J Cancer Res. 2022 May 15;12(5):2387-2396. （IF:5.94）
8.Li M#, Hou X#, Zheng L#, Ma Y, Li D, Lv Y, Chen J, Zheng W, Shao Y, Mou Y*, Chen L*. Utilizing phenotypic characteristics of metastatic brain tumors to improve the probability of detecting circulating tumor DNA from cerebrospinal fluid in non-small-cell lung cancer patients: development and validation of a prediction model in a prospective cohort study. ESMO Open. 2022 Feb;7(1):100305. （IF:6.88）
9.Li M#, Hou X#, Chen J#, Zhang B, Wang N, Han H, Chen L*. ALK fusion variant 3a/b, concomitant mutations, and high PD-L1 expression were associated with unfavorable clinical response to second-generation ALK TKIs in patients with advanced ALK-rearranged non-small cell lung cancer (GASTO 1061). Lung Cancer. 2022 Jan 12;165:54-62. （IF:6.081）
10.Liang RB#, Li P#, Li BT#, Jin JT#, Rusch VW, Jones DR, Wu YL, Liu Q, Yang J, Yang MZ, Li S, Long H, Fu JH, Zhang LJ, Lin P, Rong TH, Hou X*, Lin SX*, Yang HX*. Modification of Pathologic T Classification for Non-small Cell Lung Cancer With Visceral Pleural Invasion: Data From 1,055 Cases of Cancers ≤ 3 cm. Chest. 2021 Mar 18:S0012-3692(21)00500-6. （IF:10.26）
11.Chen X#, Zhang Z#, Hou X#, Zhang Y, Zhou T, Liu J, Lin Z, Fang W, Yang Y, Ma Y, Huang Y, Zhao H, Zhang L*. Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis. J Immunother Cancer. 2020 Aug;8(2): e001170. (IF: 9.91)
12.Chen XR#, Hou X #, Dinglin XX#, Liu YD, Li Y, Zheng W, Li DL, Chen J, Wu XL, Wang KC, Ma SX, Zeng YD, Chen LK*. Treatment Patterns and Survival Outcomes of Non-Small Cell Lung Cancer Patients Initially Diagnosed With Brain Metastases in Real-World Clinical Practice. Front Oncol. 2020 Oct 9;10:581729. （IF:5.74）

13. Hou X#, Xu H, Chen L*.SRBD1-ALK, a Novel ALK Fusion Gene Identified in an Adenocarcinoma Patient by Next-Generation Sequencing. J Thorac Oncol. 2019 Apr;14(4):e72-e73. (IF: 10.34)

Updated by International Office, Sun Yat-sen University Cancer Center